Thu Sep 19 05:45:51 UTC 2024: ## Laboratory Co. of America Holdings (LH) Earnings Estimates Lowered by Leerink Partners

**New York, NY** – Leerink Partners has lowered its earnings per share (EPS) estimates for Laboratory Co. of America Holdings (LH) for the fiscal year 2024. Analyst M. Cherny now forecasts the medical research company to earn $14.59 per share, down from the previous estimate of $14.70. This revised estimate is slightly below the current consensus estimate of $14.67 per share.

Leerink Partners also provided EPS estimates for Laboratory Co. of America’s upcoming quarters: $3.72 for Q1 2025, $3.93 for Q2 2025, $4.01 for Q3 2025, $3.97 for Q4 2025, and $22.29 for FY2028.

Despite the lowered estimates, other research analysts remain optimistic about Laboratory Co. of America’s future. Bank of America raised its price objective from $240.00 to $260.00 and maintained a “buy” rating, while Truist Financial increased its price objective from $255.00 to $275.00, also retaining a “buy” rating.

MarketBeat.com currently assigns Laboratory Co. of America a consensus rating of “Moderate Buy” with a target price of $250.82.

In recent company news, Laboratory Co. of America reported strong Q2 earnings, surpassing analyst expectations. The company’s revenue also exceeded estimates, showing a 6.2% increase year-over-year. The company also announced a quarterly dividend of $0.72 per share.

However, insider trading activity saw several executives sell shares of the company’s stock recently. EVP Der Vaart Sandra D. Van sold 2,000 shares, while EVP Lance Berberian sold 12,093 shares. Overall, insiders sold 29,679 shares worth $6,716,306 over the last quarter.

Institutional investor activity in Laboratory Co. of America has been mixed. While some firms like Janney Montgomery Scott LLC and Great Lakes Advisors LLC increased their holdings, others like Quadrant Capital Group LLC and Independent Advisor Alliance also acquired new positions or expanded their existing ones.

Despite the lowered earnings estimates from Leerink Partners, Laboratory Co. of America remains a company with strong growth potential. The company’s robust financial performance and continued investment in research and development make it a promising player in the life sciences industry. However, investors should closely monitor the company’s future earnings reports and insider trading activities to make informed investment decisions.

Read More